Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A N Bartlett

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
British Medical Journal (Clinical Research Ed.)|February 22, 1986
Pseudo food allergyR Finn, A N Bartlett
British Journal of Haematology|October 1, 1990
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observationsA N Bartlett, A V Hoffbrand, G J Kontoghiorghes
Progress in Clinical and Biological Research|January 1, 1989
Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridinesG J Kontoghiorghes, A N Bartlett, A V Hoffbrand
Clinical Pharmacology and Therapeutics|September 1, 1990
Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-oneG J Kontoghiorghes, J G Goddard, A N Bartlett, et al.
Arzneimittel-Forschung|January 1, 1995
Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changesG J Kontoghiorghes, A N Bartlett, L Sheppard, et al.
American Heart Journal|August 1, 1993
Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytesM Mosseri, A N Bartlett-Pandite, K Wenc, et al.
Lancet (London, England)|August 19, 1989
Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trialA V Hoffbrand, A N Bartlett, P A Veys, et al.
British Journal of Haematology|October 1, 1990
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studiesG J Kontoghiorghes, A N Bartlett, A V Hoffbrand, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
British Medical Journal (Clinical Research Ed.)|February 22, 1986
Pseudo food allergyR Finn, A N Bartlett
British Journal of Haematology|October 1, 1990
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observationsA N Bartlett, A V Hoffbrand, G J Kontoghiorghes
Progress in Clinical and Biological Research|January 1, 1989
Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridinesG J Kontoghiorghes, A N Bartlett, A V Hoffbrand
Clinical Pharmacology and Therapeutics|September 1, 1990
Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-oneG J Kontoghiorghes, J G Goddard, A N Bartlett, et al.
Arzneimittel-Forschung|January 1, 1995
Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changesG J Kontoghiorghes, A N Bartlett, L Sheppard, et al.
American Heart Journal|August 1, 1993
Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytesM Mosseri, A N Bartlett-Pandite, K Wenc, et al.
Lancet (London, England)|August 19, 1989
Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trialA V Hoffbrand, A N Bartlett, P A Veys, et al.
British Journal of Haematology|October 1, 1990
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studiesG J Kontoghiorghes, A N Bartlett, A V Hoffbrand, et al.
Pageof 1